Skip to main content
. 2014 Mar 20;5(5):1382–1389. doi: 10.18632/oncotarget.1837

Figure 3. Activation of major signaling pathways in endothelial cells downstream of integrin α3β1.

Figure 3

A, Time-dependent activation of Src, p38, and MEK1/2 in endothelial cells following their interaction with tumor cells for the indicated time periods. B, Anti-α3β1 function blocking antibody P1B5 inhibits time-dependent activation of Src, p38, and MEK1/2 in endothelial cells following their interaction with tumor cells for the indicated time periods. The experiments were repeated at least three times for each setting with similar results.